Results of a Phase 2 multicenter, randomized, multi-dose, placebo-controlled, clinical trial (NCT01683409) demonstrated that the oral drug Baracitinib, which selectively inhibits JAK1 and JAK2, attenuated UAE in a dose dependent manner in patients with DN with residual macroalbuminuria on RAS blockade, demonstrating its potential utility in the treatment of DN [85]. Here, JAK1 is linked to liver dysplastic nodule.